Cite
HARVARD Citation
Goto, K. et al. (n.d.). Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet oncology. 17 (8), pp. 1147-1157. [Online].